{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:48:13Z","timestamp":1790038093591,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pharmacogenomics (PGx) uses genetic information to personalize medication, reducing adverse reactions and improving efficacy. Despite its promise, low public awareness and disparities in PGx acceptability among under-represented groups may exacerbate health inequalities. The objective of this study was to elucidate a British South Asian community\u2019s attitudes toward personalised prescribing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults of Bangladeshi or Pakistani ancestry from the Genes &amp; Health (G&amp;H) study completed a survey. Community feedback guided theme prioritization. Multivariable logistic regression analyses (controlling for age and gender) explored relationships among survey variables, and case\u2013control Genome Wide Association Studies (GWAS) and candidate variant enrichment analysis examined the genetic architecture underlying herbal remedy use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Out of 553 respondents (57% female, mostly aged 25\u201354), 72% reported medication inefficacy, and 54% experienced side effects. Herbal remedies were widely used (66%), notably Black seed (39%), Turmeric (37%), and Ginger (36%). Participants who reported not using traditional or herbal medicines had higher medication adherence MARS-5 scores (Odds Ratio (OR) 1.10, 95% Confidence Interval (CI) 1.05\u20131.16,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0002). All three commonly used herbal remedies inhibit the pharmacogenomically variable CYP2C9 enzyme responsible for metabolising commonly used medications. 58% of respondents were willing to provide DNA samples for PGx testing, yet 70% agreed that they would be more likely to take medication as instructed if PGx results suggested the medicine would suit them. Concerns about PGx testing were common (27%), especially among non-English speakers. Most (69%) were concerned about misuse of PGx data, particularly by pharmaceutical companies (82%). Importantly, 87% demanded stronger PGx data protections compared to other health data.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared to a national UK population, the surveyed subpopulation reported higher rates of adverse drug reactions (ADRs) and perceived medication inefficacy, yet fewer respondents indicated willingness to undergo PGx testing. This highlights the need for tailored implementation strategies and underscores the importance of engaging underrepresented populations in policy development. The inverse relationship between medication adherence and herbal remedy use indicates an association between cultural health practices and medication behaviours that merits further investigation. Increased awareness of the common use of these CYP2C9 inhibitors and further research into the genetic architecture underlying herbal remedy use are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-026-04914-9","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:22:58Z","timestamp":1778869378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Survey to inform personalised prescribing in a British South Asian community: pharmacogenomics and traditional medicine use"],"prefix":"10.1186","volume":"24","author":[{"given":"Emma F","family":"Magavern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Marengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Kanoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahendra G","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Spreckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehru","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taleah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Genes & Health Research Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J","family":"Caulfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"4914_CR1","unstructured":"How EMA evaluates medicines for human use European Medicines Agency. How EMA evaluates medicines for human use. https:\/\/www.ema.europa.eu\/en\/about-us\/what-we-do\/authorisation-medicines\/how-ema-evaluates-medicines-human-use#related-content-19198. Accessed 3 Feb 2026."},{"key":"4914_CR2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/520609a","volume":"520","author":"NJ Schork","year":"2015","unstructured":"Schork NJ. Personalized medicine: Time for one-person trials. Nature. 2015;520:609\u201311.","journal-title":"Nature"},{"key":"4914_CR3","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/s41576-022-00572-8","volume":"24","author":"M Pirmohamed","year":"2023","unstructured":"Pirmohamed M. Pharmacogenomics: current status and future perspectives. Nat Rev Genet. 2023;24:350\u201362.","journal-title":"Nat Rev Genet"},{"key":"4914_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14983","author":"EF Magavern","year":"2021","unstructured":"Magavern EF, Gurdasani D, Ng FL, Lee SS. Health equality, race and pharmacogenomics. Br J Clin Pharmacol. 2021. https:\/\/doi.org\/10.1111\/bcp.14983.","journal-title":"Br J Clin Pharmacol"},{"key":"4914_CR5","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.cell.2019.04.032","volume":"177","author":"G Sirugo","year":"2019","unstructured":"Sirugo G, Williams SM, Tishkoff SA. The Missing Diversity in Human Genetic Studies. Cell. 2019;177:1080.","journal-title":"Cell"},{"key":"4914_CR6","unstructured":"(2022) Ethnic group, England and Wales: Census 2021: The ethnic groups of usual residents and household ethnic composition in England and Wales, Census 2021 data."},{"key":"4914_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41397-023-00317-8","volume":"23","author":"EF Magavern","year":"2023","unstructured":"Magavern EF, Durrani F, Raza M, Lerner R, Islam MR, Clinch M, Caulfield MJ. British South Asian ancestry participants views of pharmacogenomics clinical implementation and research: a thematic analysis. Pharmacogenomics J. 2023;23:185\u201394.","journal-title":"Pharmacogenomics J"},{"key":"4914_CR8","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1002\/ptr.5911","volume":"31","author":"SK Bhamra","year":"2017","unstructured":"Bhamra SK, Slater A, Howard C, Johnson M, Heinrich M. The Use of Traditional Herbal Medicines Amongst South Asian Diasporic Communities in the UK. Phytother Res. 2017;31:1786\u201394.","journal-title":"Phytother Res"},{"key":"4914_CR9","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1002\/cpt.2122","volume":"109","author":"G McInnes","year":"2021","unstructured":"McInnes G, Lavertu A, Sangkuhl K, Klein TE, Whirl-Carrillo M, Altman RB. Pharmacogenetics at Scale: An Analysis of the UK Biobank. Clin Pharmacol Ther. 2021;109:1528\u201337.","journal-title":"Clin Pharmacol Ther"},{"key":"4914_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/ije\/dyz174","volume":"49","author":"S Finer","year":"2020","unstructured":"Finer S, Martin HC, Khan A, et al. Cohort Profile: East London Genes & Health (ELGH), a community-based population genomics and health study in British Bangladeshi and British Pakistani people. Int J Epidemiol. 2020;49:20\u2013i21.","journal-title":"Int J Epidemiol"},{"key":"4914_CR11","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/bcp.14193","volume":"86","author":"AHY Chan","year":"2020","unstructured":"Chan AHY, Horne R, Hankins M, Chisari C. The Medication Adherence Report Scale: A measurement tool for eliciting patients\u2019 reports of nonadherence. Br J Clin Pharmacol. 2020;86:1281\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"4914_CR12","unstructured":"RStudio Team. (2022) RStudio: Integrated Development Environment for R."},{"key":"4914_CR13","unstructured":"PHARMGKB PHARMGKB. Gene-specific Information Tables for CYP2C9, CYP2C9 Frequency Table. https:\/\/www.pharmgkb.org\/page\/cyp2c9RefMaterials. Accessed 6 Mar 2025."},{"key":"4914_CR14","unstructured":"PHARMGKB: CYP2C9*2. https:\/\/www.pharmgkb.org\/haplotype\/PA165816543. Accessed 18 Mar 2025."},{"key":"4914_CR15","unstructured":"PHARMGKB: CYP2C9*3. https:\/\/www.pharmgkb.org\/haplotype\/PA165816544. Accessed 18 Mar 2025."},{"key":"4914_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcaf035","author":"EF Magavern","year":"2025","unstructured":"Magavern EF, Marengo G, Sivathasan C, et al. A United Kingdom nationally representative survey of public attitudes towards pharmacogenomics. QJM: Int J Med. 2025. https:\/\/doi.org\/10.1093\/qjmed\/hcaf035.","journal-title":"QJM: Int J Med"},{"key":"4914_CR17","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1111\/bcp.16058","volume":"90","author":"JH McDermott","year":"2024","unstructured":"McDermott JH, Sharma V, Newman WG, Wilson P, Payne K, Wright S. Public preferences for pharmacogenetic testing in the NHS: Embedding a discrete choice experiment within service design to better meet user needs. Br J Clin Pharmacol. 2024;90:1699\u2013710.","journal-title":"Br J Clin Pharmacol"},{"key":"4914_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/tpj.2011.11","volume":"11","author":"HC Howard","year":"2011","unstructured":"Howard HC, Joly Y, Avard D, Laplante N, Phillips M, Tardif JC. Informed consent in the context of pharmacogenomic research: ethical considerations. Pharmacogenomics J. 2011;11:155\u201361.","journal-title":"Pharmacogenomics J"},{"key":"4914_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/tpj.2011.1","volume":"12","author":"SB Haga","year":"2012","unstructured":"Haga SB, O\u2019Daniel JM, Tindall GM, Lipkus IR, Agans R. Survey of US public attitudes toward pharmacogenetic testing. Pharmacogenomics J. 2012;12:197\u2013204.","journal-title":"Pharmacogenomics J"},{"key":"4914_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000354785","volume":"17","author":"VA Diaz","year":"2014","unstructured":"Diaz VA, Mainous AG III, Gavin JK, Wilson D. Racial Differences in Attitudes toward Personalized Medicine. Public Health Genomics. 2014;17:1\u20136.","journal-title":"Public Health Genomics"},{"key":"4914_CR21","first-page":"393","volume":"5","author":"JL Bevan","year":"2003","unstructured":"Bevan JL, Lynch JA, Dubriwny TN, Harris TM, Achter PJ, Reeder AL, Condit CM. Informed lay preferences for delivery of racially varied pharmacogenomics. Genet Sci. 2003;5:393\u20139.","journal-title":"Genet Sci"},{"key":"4914_CR22","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/S0140-6736(21)00945-4","volume":"397","author":"MG Patel","year":"2021","unstructured":"Patel MG, Dorward J, Yu L-M, Hobbs FR, Butler CC. Inclusion and diversity in the PRINCIPLE trial. Lancet. 2021;397:2251\u20132.","journal-title":"Lancet"},{"key":"4914_CR23","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/jgc4.1576","volume":"31","author":"L Passero","year":"2022","unstructured":"Passero L, Srinivasan S, Roberts MC. Examining the role of language competency in genetic testing awareness among adults in the United States. J Genet Couns. 2022;31:1054\u201361.","journal-title":"J Genet Couns"},{"key":"4914_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15060247","author":"R Amato","year":"2025","unstructured":"Amato R, Del Toro-Pagan NM, Nguyen H, Plummer J, Pizzolato K, Krause D, Dowd D. Assessing the Impact of Simplified Language on a Patient-Facing Pharmacogenetic Report: A User Comprehension Study. J Pers Med. 2025. https:\/\/doi.org\/10.3390\/jpm15060247.","journal-title":"J Pers Med"},{"key":"4914_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jep.2017.07.022","volume":"209","author":"R Bahramsoltani","year":"2017","unstructured":"Bahramsoltani R, Rahimi R, Farzaei MH. Pharmacokinetic interactions of curcuminoids with conventional drugs: A review. J Ethnopharmacol. 2017;209:1\u201312.","journal-title":"J Ethnopharmacol"},{"key":"4914_CR26","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jsps.2018.02.024","volume":"26","author":"AA Albassam","year":"2018","unstructured":"Albassam AA, Ahad A, Alsultan A, Al-Jenoobi FI. Inhibition of cytochrome P450 enzymes by thymoquinone in human liver microsomes. Saudi Pharm J. 2018;26:673\u20137.","journal-title":"Saudi Pharm J"},{"key":"4914_CR27","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/aps.2013.49","volume":"34","author":"M Li","year":"2013","unstructured":"Li M, Chen P, Yue Q, Li J, Chu R, Zhang W, Wang H. Pungent ginger components modulates human cytochrome P450 enzymes in vitro. Acta Pharmacol Sin. 2013;34:1237\u201342.","journal-title":"Acta Pharmacol Sin"},{"key":"4914_CR28","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cpt.2350","volume":"110","author":"M Whirl-Carrillo","year":"2021","unstructured":"Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn CF, Whaley R, Klein TE. An Evidence\u2010Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. Clin Pharmacol Ther. 2021;110:563\u201372.","journal-title":"Clin Pharmacol Ther"},{"key":"4914_CR29","unstructured":"PHARMGKB PHARMGKB:CYP2C9 Clinical Annotations. https:\/\/www.pharmgkb.org\/gene\/PA126\/clinicalAnnotation. Accessed 6 Mar 2025."},{"key":"4914_CR30","first-page":"135","volume":"14","author":"S Nizamuddin","year":"2021","unstructured":"Nizamuddin S, Dubey S, Singh S, Sharma S, Machha P, Thangaraj K. CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations. Pharmgenomics Pers Med Volume. 2021;14:135\u201347.","journal-title":"Pharmgenomics Pers Med Volume"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04914-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04914-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04914-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:49:25Z","timestamp":1783640965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04914-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4914"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04914-9","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Queen Mary University of London Research Ethics Committee (QMERC22.353). Written informed consent was obtained for participation in the study. Participants were given a 10 GBP voucher to thank them for their time and participation upon survey completion. All responses were anonymous. A favourable ethical opinion for the main Genes & Health research study was granted by NRES Committee London - South East (reference 14\/LO\/1240) on 16 Sept 2014. Queen Mary University of London is the Sponsor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable (no individual level date included).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"We engaged with the G&H community advisory board, engagement team and participants to design this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient and Public Involvement"}}],"article-number":"387"}}